咖啡因在新生儿中的应用进展-唐晓艳

DOI10.3969/[e-mail]··apneaofprematurityAOP＜34AOP。AOP、。methylxanthinesAOP301-2、。3NICU“”1-3。24。、、。、1.1。A1A2A、、5-、。、、、、。γ-GABAA2A5-6。A1。7。2.185%。7～9。8。7-N-。P4504CYP2C8。7-N-CYP1A2CYP2C8/9CYP3A4。CYP1A2CYP2C8/9。。9。20071542920～25mg/kg16mg/kg14257518～23mg/L。、、9。200811024～29、570～1570g10101h。、1.AOP。1。3。2.FDA20mg/kg10mg/kg15mg/kg10。2003Steer30、15、3mg/kg24h·343·201429511。20mg/kg5mg/kg12-13。25mg/kg20%10mg/kg4h14。5～8mg/kg10mg/kg1。20mg/kg·d。33～34。34。1mg/kgmg/kg342020～805～105～8105～203450%328～20mg/L。3233。33～34。。285mg/kg5～20mg/L、、。3.19992004AOPCaffeineforapneaofprematuritytrialCAP2006500～1250g1020mg/kg5mg/kg。33724～4634.433.0～35.915。CAP。Steer161～35～7。、。CAP17。18。104、、。。119-20。CochraneCAPAOP。、1.Cochrane21。＜3212733、15、30mg/kg11。2004Steer20mg/kg5mg/kg13。。2.BPDBPD36。CAP、1。BPD36.3%46.9%。3。2014229511250g198629653～10。BPD36.1%46.7%22。Patel23·443·2014295833573BPD。。24h、/。24。3.。。ＲOP25。。26。4.PDA201422951＜1250g2PDA22。CAPPDA29%38%。4.5%12.6%。PDA。5.A127。3A1。A1。。CAP＜1250g33418、40.2%46.2%P=0.0084.4%7.3%。2012、、1640500～1250g5。28。6.ＲOP。。Schmidt1528～3334。18～21、。5mg/kg20mg/kg14.812.9。、、、。NEC。cAMP。2080pH。。25～50mg/kg。20mg/kg3。CAP20mg/kg·d5mg/kg·dNEC。23～10NEC23。、NICU1523。、。、、、-。。、·543·2014295。、、。＜1250g。3。。。33～34、。34、。1ArandaJVBeharryKValenciaGBetal．Caffeineimpactonneonatalmorbidities．JMaternFetalNeonatalMed20102320-23．2PiconeSBedettaMPaolilloP．Caffeinecitratewhenandforhowlong．Aliteraturereview．JMaternFetalNeonatalMed20122511-14．3NatarajanGBoticaMLArandaJV．PharmacologyＲeviewClinicalpharmacologyofcaffeineinthenewborn．NeoＲeviews20078214-221．4．．200930518-522．5MayerCAHaxhiuMAMartinＲJetal．AdenosineA2AreceptorsmediateGABAergicinhibitionofrespirationinimmaturerats．JApplPhysiol1985200610091-97．6WilsonCGMartinＲJJaberMetal．AdenosineA2AreceptorsinteractwithGABAergicpathwaystomodulaterespirationinneonatalpiglets．ＲespirPhysiolNeurobiol2004141201-211．7KumralATuzunFYesilirmakDCetal．Geneticbasisofapnoeaofprematurityandcaffeinetreatmentresponseroleofadenosinereceptorpolymorphismsgeneticbasisofapnoeaofprematurity．ActaPaediatr2012101e299-303．8KotMDanielWA．TherelativecontributionofhumancytochromeP450isoformstothefourcaffeineoxidationpathwaysaninvitrocomparativestudywithcDNA-expressedP450sincludingCYP2Cisoforms．BiochemPharmacol200876543-551．9LeonAEMichienziKMaCXetal．Serumcaffeineconcentrationsinpretermneonates．AmJPerinatol20072439-47．10CharlesBGTownsendSＲSteerPAetal．Caffeinecitratetreatmentforextremelyprematureinfantswithapneapopulationpharmacokineticsabsolutebioavailabilityandimplicationsfortherapeuticdrugmonitoring．TherDrugMonit200830709-716．11SteerPAFlenadyVJShearmanAetal．Periextubationcaffeineinpretermneonatesarandomizeddoseresponsetrial．JPaediatrChildHealth200339511-515．12GrayPHFlenadyVJCharlesBGetal．CaffeinecitrateforverypreterminfantsEffectsondevelopmenttemperamentandbehaviour．JPaediatrChildHealth201147167-172．13SteerPFlenadyVShearmanAetal．Highdosecaffeinecitrateforextubationofpreterminfantsarandomisedcontrolledtrial．ArchDisChildFetalNeonatalEd200489F499-503．14TracyMBKlimekJHinderMetal．DoescaffeineimpaircerebraloxygenationandbloodflowvelocityinpreterminfantsActaPaediatr2010991319-1323．15SchmidtBＲobertsＲSDavisPetal．Long-termeffectsofcaffeinetherapyforapneaofprematurity．NEnglJMed20073571893-1902．16SteerPAHenderson-SmartDJ．Caffeineversustheophyllineforapneainpreterminfants．CochraneDatabaseSystＲev20002CD000273．17Henderson-SmartDJDePaoliAG．Methylxanthinetreatmentforapnoeainpreterminfants．CochraneDatabaseSystＲev201012CD000140．18Henderson-SmartDJDePaoliAG．Prophylacticmethylxanthineforpreventionofapnoeainpreterminfants．CochraneDatabaseSystＲev201012CD000432．19SkouroliakouMBacopoulouFMarkantonisSL．Caffeineversustheophyllineforapneaofprematurityarandomisedcontrolledtrial．JPaediatrChildHealth200945587-592．20Henderson-SmartDJSteerP．Prophylacticcaffeinetopreventpostoperativeapneafollowinggeneralanesthesiainpreterminfants．CochraneDatabaseSystＲev20014CD000048．21Henderson-SmartDJDavisPG．Prophylacticmethylxanthinesforendotrachealextubationinpreterminfants．CochraneDatabaseSystＲev201012CD000139．22TahaDKirkbySNawabUetal．Earlycaffeinetherapyforpreventionofbronchopulmonarydysplasiainpreterminfants．JMaternFetalNeonatalMed2014．23PatelＲMLeongTCarltonDPetal．Earlycaffeinetherapyandclinicaloutcomesinextremelypreterminfants．JPerinatol201333134-140．24KassimZGreenoughAＲaffertyGF．Effectofcaffeineonrespiratorymusclestrengthandlungfunctioninprematurelybornventilatedinfants．EurJPediatr20091681491-1495．25DiFioreJMBloomJNOrgeFetal．Ahigherincidenceofintermittenthypoxemicepisodesisassociatedwithsevereretinopathyofprematurity．JPediatr201015769-73．26SchoenK．Useofmethylxanthinetherapiesforthetreatmentandpreventionofapneaofprematurity．PaediatrDrugs201416p169-177．27GaytanSPPasaroＲ．Neonatalcaffeinetreatmentup-regulatesadenosinereceptorsinbrainstemandhypothalamiccardio-respiratoryrelatednucleiofratpups．ExpNeurol2012237247-259．28DoyleLWCheongJHuntＲWetal．Caffeineandbraindevelopmentinverypreterminfants．AnnNeurol201068734-742．2014-03-13·643·2014295